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MF59-adjuvanted trivalent influenza vaccine (Novartis Vaccines and Diagnostics, Siena, Italy) has been shown to
be more effective than nonadjuvanted vaccine in the elderly population. Here we present results from a large-scale,
observational, noninterventional, prospective postlicensure study that evaluated the safety of MF59-adjuvanted vac-
cine in elderly subjects aged 65 years or more. The study was performed in 5 northern Italian health districts during
the 2006–2007, 2007–2008, and 2008–2009 influenza seasons. The choice of vaccine—either adjuvanted vaccine
or a nonadjuvanted influenza vaccine—was determined by individual providers on the basis of local influenza vacci-
nation policy. Hospitalizations for potential adverse events of special interest (AESIs) were identified from hospital
databases and then reviewed against recognized case definitions to identify confirmed cases of AESI. Cumulative
incidences were calculated for AESIs in predefined biologically plausible time windows, as well as in a 6-month win-
dow following vaccination. During the 3-year study period, 170,988 vaccine doses were administered to a total of
107,661 persons. Despite the large study size, cases of AESI resulting in hospitalization were rare, and risks of AESI
were similar in both the MF59-adjuvanted and nonadjuvanted vaccination groups. In conclusion, similar safety profiles
were observed for both nonadjuvanted and MF59-adjuvanted seasonal influenza vaccines in elderly recipients.
adjuvants; elderly; influenza; influenza vaccine; MF59; vaccines; vaccine safety
Abbreviations: AESI, adverse event of special interest; ATIV, adjuvanted trivalent influenza vaccine; ICD-9, International
Classification of Diseases, Ninth Revision; LIVE, Lombardia Influenza Vaccine Effectiveness; TIV, trivalent influenza vaccine.
Inﬂuenza infection is a major cause of illness, morbidity,
and mortality throughout the world. The World Health Orga-
nization has estimated that inﬂuenza affects 5%–15% of the
global population each year (1). Groups at high risk for inﬂu-
enza complications include the elderly, patients with chronic
pulmonary and cardiovascular conditions, and institutional-
ized persons such as people in nursing homes (2). While rou-
tine inﬂuenza vaccination of the elderly is supported by
clinical and economic evidence of its effectiveness in reduc-
ing morbidity and mortality (3), several studies have shown
that the effectiveness of vaccination is not optimal, ranging from
30% to 70% in preventing hospitalization for pneumonia (4).
Observational studies in nursing home residents have shown
50%–60%effectiveness (5). Part of the explanation for this sub-
optimal level of effectiveness is immunosenescence, which
leads to lower immunogenicity of nonadjuvanted inﬂuenza
vaccines in the elderly as compared with young adults (6). To
address this issue, adjuvanted inﬂuenza vaccines have been
developed. The MF59-adjuvanted trivalent inﬂuenza vaccine
(ATIV) Fluad (Novartis Vaccines and Diagnostics, Siena,
Italy) has been in use in Europe since 1997, with more than
50 million doses having been administered. Several studies
have shown that this vaccine provides improved immunoge-
nicity as well as broader protection against heterosubtypic or
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antigenically drifted strains of inﬂuenza in comparison with
nonadjuvanted trivalent inﬂuenza vaccine (TIV) (7).
While reports from clinical studies and passive surveil-
lance systems in several countries have shown this vaccine
to be safe and well tolerated, a large prospective systematic
assessment of safety in the elderly has not been performed.
Here we report results from such an assessment, a study con-
ducted among elderly adults (ages ≥65 years) in the north-
ern Italian region of Lombardy.
MATERIALS ANDMETHODS
The Lombardia Inﬂuenza Vaccine Effectiveness (LIVE)
Study (8) was an observational, noninterventional, prospective
cohort study performed in the Italian local health authorities
of Cremona, Mantova, Pavia, Lecco, and Bergamo during the
2006–2007, 2007–2008, and 2008–2009 inﬂuenza seasons to
compare the effectiveness of the ATIV, Fluad, and a nonadju-
vanted TIV, Agrippal (Novartis Vaccines and Diagnostics).
The current safety evaluation was a secondary objective of the
LIVE Study. The study location was chosen because of the
highly developed computerized clinical information systems
available in the Lombardy region and the considerable experi-
ence with performing pharmacoepidemiologic studies in this
population.
Residents aged ≥65 years seeking inﬂuenza vaccination at
local health authorities’ district ofﬁces or the ofﬁces of partici-
pating general practitioners were eligible for enrollment. Sub-
jects who were currently institutionalized or had been in a
nursing or rehabilitation center within 30 days before the start
of the study were excluded. Eligible subjects were informed
by the vaccinators about the studyand asked for their consent to
participate. The assignment of ATIV or TIV was determined
by the individual providers in conformancewith local inﬂuenza
vaccination policy. According to Italian guidelines, adjuvanted
vaccine was preferentially recommended for elderly persons
withunderlyingchronicconditions.Thiswasa3-yearstudy,and
participants could be enrolled for multiple years. All study par-
ticipants were provided with a brief questionnaire on basic
medical history, smoking status, functional status, and inﬂuenza
vaccinationhistory for theprioryear.The typeofvaccine received
was recorded in the study database. More details about the
operational procedures of the LIVE Study are provided else-
where (8).
Using lists of serious safety outcomes developed by the
US Food and Drug Administration, the European Centre for
Disease Control, and theWorld Health Organization to assess
the safety of the inﬂuenza vaccines, we developed a prespec-
iﬁed list of adverse events of special interest (AESIs) (9). To
increase case ascertainment, we used a broad list of Interna-
tionalClassiﬁcation ofDiseases,NinthRevision (ICD-9), codes
thatwere designed tobe sensitive rather than speciﬁc (Appendix
Table 1). Using a patient identiﬁer (the Italian National Fis-
cal Code) unique to each person receiving care within the
Italian health-care system, all hospitalizations with any of the
listed ICD-9 codes occurring before or during the study
period were identiﬁed. All potential cases underwent clinical
validation. Brighton Collaboration deﬁnitions and classiﬁcation
schemes (https://brightoncollaboration.org/public/what-we-do/
setting-standards/guidelines.html)wereusedpreferentiallywhen
available; when they were not available, recognized classiﬁca-
tionschemesdevelopedbynationalspecialtyorganizationswere
used (Appendix Table 2).
Clinical validation of all potential cases of AESI identiﬁed
through record linkage was performed according to a prede-
ﬁned validation plan andwasmanaged by the coordinating study
center (the Cremona Local Health Authority). The Cremona
Local Health Authority requested and obtained paper copies of
patients’medical charts from all hospitals identiﬁed by record
linkage as having discharged study subjects with a diagnosis
code for an AESI. Depending on the type of AESI experi-
enced, the medical charts (blinded with respect to subjects’
identity, condition, and time of vaccination) were examined
by one of 2 independent teams of medical experts, one for
immunology-related AESIs and one for neurological events.
The medical teams convened to evaluate the cases according
to their areas of expertise at the premises of the Cremona
Local Health Authority. The immunology team included 2
medical experts. The ﬁrst expert examined the clinical docu-
mentation received from the hospitals and expressed his
opinion on each case, while the second reviewed the valida-
tion performed by his colleague and had the ultimate respon-
sibility for deciding the ﬁnal adjudication category, which
was either “deﬁnite,” “probable,” “possible,” “cannot be ruled
out,” or “ruled out.” Similarly, the medical team responsible
for neurological events included 3 experts, 2 of whom per-
formed the initial clinical validation, while the third was in
charge of the ﬁnal adjudication. The development of the vali-
dation protocol was performed by RTI Health Solutions
(Research Triangle Park, North Carolina). The reviewers
and adjudicators were all expert physicians from academic
institutions.
According to a prespeciﬁed analysis plan, the primary anal-
ysis for each AESI involved calculating the cumulative inci-
dence, as well as the risk difference and binomial exact 95%
conﬁdence interval, for new-onset cases classiﬁed as either
“deﬁnite,” “probable,” or “possible,” that occurred during the
biologically plausible timewindow for each outcome, as deﬁned
by the World Health Organization, the US Food and Drug
Administration, and the European Centre for Disease Control.
An additional secondary analysis was performed for similarly
conﬁrmed hospitalizations occurring within 6 months of vac-
cination. For each of these time frames, secondary sensitivity
analyses were performed that included cases for the outcome
classiﬁed as “cannot be ruled out,” in addition to the “deﬁ-
nite,” “probable,” or “possible” cases.
Since hospital coding often includes diagnostic codes for
chronic conditions that may not have been a cause of acute
hospitalization or may not be currently active conditions, for
the chronic conditions of Bell’s palsy, encephalitis, vasculitis,
Guillain-Barré syndrome, acute transverse myelitis, demyelin-
ating disease, and optic neuritis, only cases without a history
of a hospitalization for the same condition within the past 3
months were included as incident cases in the analyses. For
anaphylaxis and convulsions, all eventswere included regard-
less of prior history.
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RESULTS
During the 3 study years, 170,988 vaccine doses (88,449
ATIV; 82,539 TIV) were administered to 107,661 study par-
ticipants. The 2 vaccine groups showed some imbalance with
respect to age, functional limitations, and prevalence of chronic
conditions (Table 1). Linkage of the study database to the
medical records hospitalization database revealed that 460
hospitalizations in 401 subjects were coded with an ICD-9
code of potential AESI during the 6-month time window; 58
hospitalizations in 56 subjects occurred within the predeﬁned
biologically plausible windows. Table 2 shows the distribu-
tion of such potential cases. The positive predictive value (i.e.,
the percentage of cases actually conﬁrmed as having the out-
come of interest out of the total number of potential cases)
of the ICD-9 code search of the medical records varied between
3% for anaphylaxis to 100% for encephalitis, with the ICD-9
code lists formanyoutcomeshavingpositivepredictivevalues of
less than 50%, thus conﬁrming the need for case adjudication.
The results of the primary and secondary analyses for the 2
timewindows (biologically plausible and 6months) are shown
in Tables 3–6. In the primary analysis for the biologically
plausible time windows (Table 3), there were no validated
events observed for Guillain-Barré syndrome, anaphylaxis,
autoimmune hepatitis, demyelinating disease, or encephalitis.
Table 2. Numbers of Hospitalizations Occurring in the Biologically
Plausible Time Windows and the 6-Month Time Window Following
Vaccination Among Vaccinees Aged ≥65 Years, Lombardy, Italy,
2006–2009
Outcome
Biologically
Plausible
Time Windows
6-Month
Time
Window
Anaphylaxis 1 33
Autoimmune hepatitis 4 19
Bell’s palsy 1 8
Convulsions 14 189
Demyelinating disorders 4 16
Encephalitis 0 1
Guillain-Barré syndrome 15 96
Immune thrombocytopenic
purpura
13 59
Vasculitis 6 39
Total 58 460
Table 1. Characteristics of Vaccinees Aged ≥65 Years at
Enrollment in the Lombardia Influenza Vaccine Effectiveness Study,
by Type of Vaccine Received, Lombardy, Italy, 2006–2009
Characteristic
Vaccine
ATIV TIV
Mean age, years 76.5 74.9
Chronic disease, %
Chronic obstructive pulmonary disease 11.9 10.4
History of pneumonia, influenza, or emphysema 3.0 2.3
Chronic kidney disease 0.9 0.7
Cancer 15.1 14.2
Diabetes 15.9 15.0
Heart disease 75.1 72.1
Vascular disease 7.2 6.1
Functional limitation in daily activities, %
Severe 16.9 12.3
Mild 30.5 27.1
None 52.6 60.6
Functional limitation in climbing stairs, %
Severe 17.3 12.8
Mild 32.8 29.6
None 49.9 57.6
Abbreviations: ATIV, adjuvanted trivalent inactivated vaccine; TIV,
trivalent inactivated vaccine.
Table 3. Numbers of “Definite,” “Probable,” and “Possible” Cases of Adverse Events of Special Interest Arising During the Biologically Plausible
Time Windows Following Receipt of ATIV (n = 88,449) and TIV (n = 82,539) Among Vaccinees Aged ≥65 Years (Primary Analysis), Lombardy,
Italy, 2006–2009
Outcome
TIV ATIV Difference
No. of Cases Riska 95% CI No. of Cases Riska 95% CI Riska 95% CI
Anaphylaxis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Autoimmune hepatitis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Bell’s palsy 0 0.00 0.00, 4.47 1 1.13 0.03, 6.30 1.13 −1.09, 3.35
Convulsions 6 7.27 2.67, 15.82 4 4.52 1.23, 11.58 −2.75 −10.06, 4.57
Demyelinating disorders 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Encephalitis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Guillain-Barré syndrome 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Immune thrombocytopenic purpura 1 1.21 0.03, 6.75 2 2.26 0.27, 8.17 1.05 −2.88, 4.98
Vasculitis 0 0.00 0.00, 4.47 2 2.26 0.27, 8.17 2.26 −0.87, 5.39
Abbreviations: ATIV, adjuvanted trivalent inactivated vaccine; CI, confidence interval; N/A, not available; TIV, trivalent inactivated vaccine.
a Cumulative incidence (number of cases per 100,000 persons).
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There was 1 case of Bell’s palsy in the ATIV group versus no
cases in the TIV group, 4 cases of convulsions in the ATIV
group versus 6 in the TIV group, 2 cases of immune thrombo-
cytopenic purpura in the ATIV group versus 1 in the TIV
group, and 2 cases of vasculitis in the ATIV group versus
none in the TIV group. In the secondary analysis, performed
using the 6-month exposure window following vaccination
(Table 4), larger numbers of events were observed, notably
for convulsions. Cases of Guillain-Barré syndrome and convul-
sion were more common in the TIV group in this analysis,
whereas there were more cases of immune thrombocytopenic
purpura in the ATIV group.
In the sensitivity analyses, which incorporated cases for
each outcome that had been classiﬁed as “cannot rule out,”
the number of events in the analyses increased as expected,
both in the biologically plausible time windows (Table 5)
and in the 6-month time window (Table 6), but there was no
indication of any adverse effect among the studied endpoints
that emerged with the addition of these borderline cases.
Despite the large size of the 2 vaccine cohorts, hospitaliza-
tion for any of the AESIs, except for convulsion, was rare in
both groups. Risks of AESI were similar in the ATIV and
TIV groups. Overall, there was no indication that receipt of
MF59-adjuvanted vaccine was associated with an increased
risk of any AESI.
DISCUSSION
To our knowledge, this was the ﬁrst large prospective
postlicensure study to evaluate the safety ofATIV in the elderly.
Observational studies based on automated data offer distinct
advantages over passive surveillance in that outcomes are sys-
tematicallyand efﬁcientlyascertained,with very limited poten-
tial for loss of outcome events leading to hospitalization. In
our case, since all hospitalizations of subjects registered
with the local health authorities are included in the database,
we can be conﬁdent that all such events were identiﬁed. In
addition, there was no risk of preferential self-reporting for
Table 4. Numbers of “Definite,” “Probable,” and “Possible” Cases of Adverse Events of Special Interest Arising During the 6-Month Time
Window Following Receipt of ATIV (n = 88,449) and TIV (n = 82,539) Among Vaccinees Aged ≥65 Years (Secondary Analysis), Lombardy, Italy,
2006–2009
Outcome
TIV ATIV Difference
No. of Cases Riska 95% CI No. of Cases Riska 95% CI Riska 95% CI
Anaphylaxis 0 0.00 0.00, 4.47 1 1.13 0.00, 6.30 1.13 −1.09, 3.35
Autoimmune hepatitis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Bell’s palsy 1 1.21 0.03, 6.75 2 2.26 0.27, 8.17 1.05 −2.88, 4.98
Convulsions 41 49.67 35.65, 67.39 39 44.09 31.36, 60.27 −5.58 −26.12, 14.97
Demyelinating disorders 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Encephalitis 1 1.21 0.03, 6.75 0 0.00 0.00, 4.17 −1.21 −3.59, 1.16
Guillain-Barré syndrome 4 4.85 1.32, 12.41 1 1.13 0.03, 6.30 −3.72 −8.96, 1.53
Immune thrombocytopenic purpura 1 1.21 0.03, 6.75 3 3.39 0.70, 9.91 2.18 −2.33, 6.69
Vasculitis 1 1.21 0.03, 6.75 5 5.65 1.84, 13.19 4.44 −1.05, 9.94
Abbreviations: ATIV, adjuvanted trivalent inactivated vaccine; CI, confidence interval; N/A, not available; TIV, trivalent inactivated vaccine.
a Cumulative incidence (number of cases per 100,000 persons).
Table 5. Numbers of “Definite,” “Probable,” “Possible,” and “Cannot Be Ruled Out” Cases of Adverse Events of Special Interest Arising During
the Biologically Plausible TimeWindows Following Receipt of ATIV (n = 88,449) and TIV (n = 82,539) Among Vaccinees Aged ≥65 Years
(Secondary Sensitivity Analysis), Lombardy, Italy, 2006–2009
Outcome
TIV ATIV Difference
No. of Cases Riska 95% CI No. of Cases Riska 95% CI Riska 95% CI
Anaphylaxis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Autoimmune hepatitis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Bell’s palsy 0 0.00 0.00, 4.47 1 1.13 0.03, 6.30 1.13 −1.09, 3.35
Convulsions 7 8.48 3.41, 17.47 4 4.52 1.23, 11.58 −3.96 −11.65, 3.73
Demyelinating disorders 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Encephalitis 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Guillain-Barré syndrome 0 0.00 0.00, 4.47 0 0.00 0.00, 4.17 0.00 N/A
Immune thrombocytopenic purpura 3 3.63 0.75, 10.62 4 4.52 1.23, 11.58 0.89 −5.16, 6.93
Vasculitis 0 0.00 0.00, 4.47 3 3.39 0.70, 9.91 3.39 −0.45, 7.23
Abbreviations: ATIV, adjuvanted trivalent inactivated vaccine; CI, confidence interval; N/A, not available; TIV, trivalent inactivated vaccine.
a Cumulative incidence (number of cases per 100,000 persons).
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one group or the other; conversely, there may have been a
higher risk of incidental ascertainment of outcome events in
the ATIV group, which was more frail and therefore more
likely to be hospitalized independently of AESI.
This study was performed in a population where persons
with chronic conditions and those who were considered fragile
weremore likely to receive adjuvanted inﬂuenzavaccine; choice
of vaccine was not random, and higher-risk patients were
preferentiallyvaccinatedwithadjuvantedvaccine.Thus,ATIV
recipients were more likely to have chronic conditions or to
be generally fragile and were therefore more likely to be hos-
pitalized.Despite this, the study generated no evidence to sug-
gest that the ATIV group had a higher risk of AESIs when
compared with the TIV group.
A limitation in the designof this studywas its reliance onhos-
pitalization events as the endpoint of interest. Less clinicallysig-
niﬁcant adverse events—that is, minor events that might result
in ambulatory visits but would not result in hospitalization—
were not assessed in this study. Because this was a prospective
cohort study with complete case ascertainment for hospitali-
zations and subsequent validation, in each vaccine cohort we
were also able to calculate cumulative incidences for these
events. Rates for all AESIs in this study were consistent with
or lower than reported population-based background rates
from other studies (9). These ﬁndings support existing data
from clinical studies and passive safety reporting (10, 11).
Altogether, data from this study indicate that MF59-adjuvanted
vaccine has a safety proﬁle similar to that of nonadjuvanted
vaccine in an elderly population.
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Appendix Table 1. International Classification of Diseases, Ninth Revision, Codes Used to Identify Potential
Cases and Biologically Plausible Time Windows for Predefined Adverse Events of Special Interest Among
Vaccinees Aged ≥65 Years, Lombardy, Italy, 2006–2009
Outcome ICD-9 Code(s) Used to Identify Potential Cases Biologically PlausibleTime Window, days
Anaphylaxis 977.8, 977.9, 979.6–979.9, 995.0–995.4, 999.4,708.0,
708.9, and E949.0–E949.9
0–2
Autoimmune hepatitis 570, 571.4, 573.3, and 573.9 0–60
Bell’s palsy 351 0–60
Convulsion 345, 779.0, 779.1, and 780.3 0–14
Demyelinating disease 323.81, 340, 341.1, 341.9, 341.2, and 377.3 0–42
Encephalitis and
encephalomyelitis
323.5, 323.8, and 323.9 0–42
Guillain-Barré syndrome 357.0, 357.6, 357.8, 357.9, and 344 0–42
Immune thrombocytopenic
purpura
279.12, 287.3–287.5, and 776.1 0–42
Vasculitis 273.2, 287.0, 362.18, 437.4, 443.1, 437.4, 446, 447.6,
and 448.9
0–42
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision.
Appendix Table 2. Source of Case Definition Used for Adverse Events of Special Interest Among Vaccinees Aged
≥65 Years, Lombardy, Italy, 2006–2009
Outcome (Reference No.) Source ofCase Definition
Guillain-Barré syndrome and Miller Fisher syndrome (12),
Bell’s palsy (13), encephalitis (14), convulsion (15),
anaphylaxis (16), immune thrombocytopenia (17)
Brighton Collaboration
Acute transverse myelitis (18) Transverse Myelitis ConsortiumWorking Group
(2002)
Optic neuritis (19) Guidelines in the published literature
Multiple sclerosis (20) Revised McDonald criteria
Vasculitis (21) American College of Rheumatology
Autoimmune hepatitis (22) International Autoimmune Hepatitis Group
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